Trial · NCT07400094
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
NCT07400094, Phase 2, Not yet recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC. Trials, record NCT07400094. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07400094
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
- NCT number
- NCT07400094
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Interventions
- Camrelizumab, Paclitaxel, carboplatin, Radical Surgery
- First posted
- 2026-02-10
- Last updated
- 2026-02-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological Complete Response (pCR) Rate | At the time of surgery (approximately 10-12 weeks from baseline) | Rate of complete pathological response (absence of viable tumor cells in resected specimen) |
| Primary | Major Pathological Response (MPR) Rate | At the time of surgery (approximately 10-12 weeks from baseline) | Rate of major pathological response (\<10% viable tumor cells in resected specimen) |
| Secondary | Objective Response Rate (ORR) | After 3 cycles of neoadjuvant therapy (approximately 9 weeks) | Rate of objective response by imaging (MRI/PET-CT) compared to historical TPF control |
| Secondary | 3-Year Event-Free Survival (EFS) | 3 years from enrollment | EFS compared to historical control (surgery + RT/CRT) |
| Secondary | Incidence of Adverse Events | From first dose until 30 days after surgery | Safety profile compared to standard TPF induction chemotherapy |
| Secondary | Proportion Requiring Adjuvant Chemoradiation | At the time of surgery | Patients needing post-op CRT due to adverse pathological features vs historical control |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38467604 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07400094
GET https://conductscience.org/api/trials/v1/NCT07400094/registered